A phase III randomised trial comparing sequential to standard chemotherapy in advanced non-small cell lung cancer (NSCLC).

被引：0
|
作者：
Sculier, J.
Lafitte, J.
Lecomte, J.
Alexopoulos, C.
Van Cutsem, O.
Giner, V.
Efremidis, A.
Scherpereel, A.
Paesmans, M.
Berghmans, T.
机构：
[1] Inst Jules Bordet, B-1000 Brussels, Belgium
[2] CHU Calmette, Lille, France
[3] CHU Charleroi, Charleroi, Belgium
[4] Evangelismos Gen Hosp, Athens, Greece
[5] Clin Univ St Luc, Namur, Belgium
[6] Hosp Sagunto, Valence, France
[7] Hellen Canc Inst, Athens, Greece
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2006年 / 24卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：367S / 367S
页数：1
相关论文
共 50 条
  • [31] Neoadjuvant Chemotherapy for Locally Advanced Non-Small Cell Lung Cancer (NSCLC) Patients
    Nakagawa, Taku
    Minamiya, Yoshihiro
    Saito, Hajime
    Imai, Kazuhiro
    Konno, Hayato
    Kudo, Satoshi
    Saito, Yoshitaro
    Kurihara, Nobuyasu
    Watanabe, Shinnosuke
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S685 - S686
  • [32] The importance of response to chemotherapy in advanced squamous non-small cell lung cancer (NSCLC).
    Hirsh, Vera
    Wan, Yin
    Whiting, Scott
    Ong, Teng Jin
    Botteman, Marc
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [33] A phase III randomised controlled trial of erlotinib vs gefitinib in advanced non-small cell lung cancer with EGFR mutations
    Yang, J. J.
    Zhou, Q.
    Yan, H. H.
    Zhang, X. C.
    Chen, H. J.
    Tu, H. Y.
    Wang, Z.
    Xu, C. R.
    Su, J.
    Wang, B. C.
    Jiang, B. Y.
    Bai, X. Y.
    Zhong, W. Z.
    Yang, X. N.
    Wu, Y. L.
    BRITISH JOURNAL OF CANCER, 2017, 116 (05) : 568 - 574
  • [34] A phase III randomised controlled trial of erlotinib vs gefitinib in advanced non-small cell lung cancer with EGFR mutations
    J J Yang
    Q Zhou
    H H Yan
    X C Zhang
    H J Chen
    H Y Tu
    Z Wang
    C R Xu
    J Su
    B C Wang
    B Y Jiang
    X Y Bai
    W Z Zhong
    X N Yang
    Y L Wu
    British Journal of Cancer, 2017, 116 : 568 - 574
  • [35] Sub-analyses of responders of a phase III trial of erlotinib combined with cisplatin and gemcitabine (GC) chemotherapy in advanced non-small cell lung cancer (NSCLC)
    Reck, Martin
    Klughammer, Barbara
    Montavon, Pierre
    Ward, Carol
    De Rosa, Flavio
    Brennscheidt, Ulrich
    Gatzemeier, Ulrich
    ANNALS OF ONCOLOGY, 2004, 15 : 169 - 170
  • [36] Two randomised phase III, double blind, placebo controlled trials of thalidomide in patients with advanced non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC)
    Lee, S.
    Rudd, R. M.
    Woll, P. J.
    Ottensmeier, C. H.
    James, L. E.
    Gower, N. H.
    Spiro, S. G.
    Jitlal, M.
    Hackshaw, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [37] Results of a phase III trial of erlotinib (OSI-774) combined with cisplatin and gemcitabine (GC) chemotherapy in advanced non-small cell lung cancer (NSCLC)
    Gatzemeier, U
    Pluzanska, A
    Szczesna, A
    Kaukel, E
    Roubec, J
    Brennscheidt, U
    De Rosa, F
    Mueller, B
    Von Pawel, J
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 619S - 619S
  • [38] CHEMOTHERAPY IN NON-SMALL CELL LUNG-CANCER (NSCLC)
    KLASTERSKY, J
    EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY, 1989, 25 (07): : 1035 - 1038
  • [39] Adjuvant chemotherapy in non-small cell lung cancer (NSCLC)
    Felip, E.
    Cedres, S.
    Peralta, S.
    Prat, A.
    ANNALS OF ONCOLOGY, 2007, 18 : 143 - 146
  • [40] CHEMOTHERAPY FOR NON-SMALL CELL LUNG-CANCER (NSCLC)
    THATCHER, N
    BRITISH JOURNAL OF CANCER, 1987, 56 (06) : 886 - 887
12345